碘曲西酸 | 51022-74-3

• 物质功能分类: 原料药 - 诊断用药 - 影象检查用药
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 碘曲西酸
• 英文名称: iotroxic acid
• 英文别名: Biliscopin；3-[[2-[2-[2-[2-(3-carboxy-2,4,6-triiodoanilino)-2-oxoethoxy]ethoxy]ethoxy]acetyl]amino]-2,4,6-triiodobenzoic acid
• CAS: 51022-74-3
• 化学式: C₂₂H₁₈I₆N₂O₉
• 分子量: 1215.82
• InChiKey: JXMIBUGMYLQZGO-UHFFFAOYSA-N

物化性质

• 密度：
  2.4781 (estimate)
• LogP：
  3.35 at 20℃

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  39
• 可旋转键数：
  14
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  161
• 氢给体数：
  4
• 氢受体数：
  9

制备方法与用途

碘酸是一种用于静脉胆道造影的医学成像剂。

文献信息

• Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers
  申请人：Bezwada Rao S.

  公开号：US20120035259A1

  公开（公告）日：2012-02-09

  The present invention provides NO and, optionally, drug releasing macromers and oligomers wherein the drug molecule and NO releasing moiety are linked an absorbable macromer or oligomeric chain susceptible to hydrolytic degradation and wherein the macromer or oligomer comprises of repeat units derived from safe and biocompatible molecules such as glycolic acid, lactic acid, caprolactone and p-dioxanone. Furthermore, the present invention relates to controlled release of nitric oxide (NO) and/or drug molecule from a NO and drug releasing macromer or oligomer. Moreover, the present invention also relates to medical devices, medical device coatings and therapeutic formulations comprising of nitric oxide and drug releasing macromers and oligomers of the present invention.

  本发明提供了一氧化氮(NO)和可选的药物释放的大分子和寡聚物，其中药物分子和一氧化氮释放部分通过可吸收的大分子或可水解降解的寡聚物链连接，并且大分子或寡聚物由来自诸如乙醇酸、乳酸、己内酰胺和对二恶烷等安全且生物相容的分子的重复单元组成。此外，本发明还涉及从一氧化氮和/或药物分子释放的大分子或寡聚物控制释放一氧化氮(NO)。此外，本发明还涉及包含本发明的一氧化氮和药物释放大分子和寡聚物的医疗器械、医疗器械涂层和治疗方法。
• ABSORBABLE BRANCHED POLYESTERS AND POLYURETHANES
  申请人：Bezwada Biomedical, LLC

  公开号：US20140142199A1

  公开（公告）日：2014-05-22

  The present invention relates to the discovery of a new class of hydrolysable isocyanates, hydrolysable branched polyols and branched absorbable polyesters and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, stents, highly porous foam, reticulated foam, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers can have a controlled hydrolytic degradation profile.

  本发明涉及一种新型可水解异氰酸酯、可水解支链多元醇及其制备的支链可吸收聚酯和聚氨酯的发现。由此得到的可吸收聚合物可用于药物输送、支架、高孔隙率泡沫、网状泡沫、组织工程、组织粘合剂、防止粘连、骨蜡制剂、医疗设备涂层、表面改性剂以及其他可植入医疗设备。此外，这些可吸收聚合物可以具有受控的水解降解特性。
• Functionalized drugs and polymers derived therefrom
  申请人：Bezwada S. Rao

  公开号：US20060172983A1

  公开（公告）日：2006-08-03

  Compounds selected from: where DRUG-OH, DRUG-COOH and DRUG-NH 2 are biologically active compounds; each X is independently selected from —CH 2 COO— (glycolic acid moiety), —CH(CH 3 )COO— (lactic acid moiety), —CH 2 CH 2 OCH 2 COO— (dioxanone moiety), —CH 2 CH 2 CH 2 CH 2 CH 2 COO— (caprolactone moiety), —(CH 2 ) y COO—, where y is 2-4 or 6-24 and —(CH 2 CH 2 O) z CH 2 COO—, where z is 2-24; each Y is independently selected from —COCH 2 O— (glycolic ester moiety), —COCH(CH 3 )O— (lactic ester moiety), —COCH 2 OCH 2 CH 2 O— (dioxanone ester moiety), —COCH 2 CH 2 CH 2 CH 2 CH 2 O— (caprolactone ester moiety), —CO(CH 2 ) m O—, where m is 2-4 or 6-24 and —COCH 2 O(CH 2 CH 2 O) n — where n is between 2-24; R′ is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; and p is 1-6. Multi-functional compounds and drug dimers, oligomers and polymers are also disclosed.

  从中选择的化合物：其中DRUG-OH，DRUG-COOH和DRUG-NH2是生物活性化合物；每个X独立地从—CH2COO—（乙二酸基团），—CH(CH3)COO—（乳酸基团），—CH2CH2OCH2COO—（二氧杂环己酮基团），—CH2CH2CH2CH2CH2COO—（己内酯基团），—(CH2)yCOO—中选择，其中y为2-4或6-24和—(CH2CH2O)zCH2COO—，其中z为2-24；每个Y独立地从—COCH2O—（乙二酸酯基团），—COCH(CH3)O—（乳酸酯基团），—COCH2OCH2CH2O—（二氧杂环己酮酯基团），—COCH2CH2CH2CH2CH2O—（己内酯酯基团），—CO(CH2)mO—，其中m为2-4或6-24和—COCH2O(CH2CH2O)n—，其中n为2-24；R′为氢，苄基或烷基，烷基可以是直链或支链；p为1-6。还披露了多功能化合物和药物二聚体、寡聚体和聚合物。
• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。